Annual case volume on mortality after coronary artery bypass grafting: a dose-response meta-analysis

Hong-Tao Tie1, Rui Shi2, Quan Zhou3

  • 1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Insights

Higher hospital and surgeon case volumes for coronary artery bypass grafting (CABG) are linked to reduced patient mortality. This inverse relationship between volume and mortality persists over time, indicating consistent benefits.

Area of Science:

  • Cardiovascular Surgery
  • Health Services Research
  • Surgical Outcomes

Background:

  • Patient outcomes after coronary artery bypass grafting (CABG) can be influenced by various factors.
  • Understanding the impact of procedural volume on mortality is crucial for quality improvement in cardiac surgery.

Purpose of the Study:

  • To evaluate the association between hospital and surgeon annual case volumes and patient mortality following CABG.
  • To determine if this association has changed over time.

Main Methods:

  • A systematic review and meta-analysis of clinical studies identified through PubMed and Embase.
  • Inclusion of studies reporting operative, in-hospital, or 30-day mortality following CABG.
  • Pooled estimation of the odds ratio (OR) for mortality based on hospital and surgeon case volumes.

Main Results:

  • Both higher hospital and surgeon annual case volumes were significantly inversely associated with mortality after CABG (OR for hospital: 0.62; OR for surgeon: 0.51).
  • High heterogeneity was observed in the pooled estimates.
  • Meta-regression and dose-response analyses indicated a robust, non-linear, and unattenuated negative association between volume and mortality over time.

Conclusions:

  • Increased hospital and surgeon annual case volumes are associated with lower mortality rates in CABG patients.
  • The beneficial effect of higher procedural volumes on mortality remains consistent and is not diminished over time.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
912
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
390
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.0K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
222
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.4K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.6K